miR-122抑制肝癌的作用及其机制研究进展  

Research Advance in Effect and Mechanism of mi R-122 in Inhibiting Hepatocellular Carcinoma

作　　者：李明芬[1] 林洪升[1] 李屏[1] 邓增富 杨磊[1] 韦巍[1] 潘爱萍[1] LI Mingfen;LIN Hongsheng;LI Ping;DENG Zengfu;YANG Lei;WEI Wei;PAN Aiping(Department of Clinical Laboratory,the First Affiliated Hospital,Guangxi University of Traditional Chinese Medicine,Nanning 530023,China)

机构地区：[1]广西中医药大学第一附属医院检验科,南宁530023

出　　处：《医学综述》2020年第6期1092-1096,共5页Medical Recapitulate

基　　金：国家自然科学基金(81603575,81960840);广西自然科学基金(2018GXNSFBA281092)。

摘　　要：原发性肝癌(PHC)是常见的恶性肿瘤,发病机制尚不明确,治疗针对性较差,治疗效果欠佳。肝脏特异性高表达的微RNA(miRNA/miR)-122与PHC的发生密切相关,其中miR-122的低表达在PHC的发生、发展、预后及肝细胞分化中起重要作用。miR-122主要通过与其靶基因结合或作用于相关信号通路参与肝癌细胞的生物学过程,发挥抑癌作用。Wnt/β联蛋白信号通路和细胞周期蛋白G1、解整合素-金属蛋白酶10、胰岛素样生长因子-1受体和叉头框蛋白家族基因等肿瘤相关基因均为miR-122的重要作用靶点。在分子生物学角度对PHC发病机制的进一步阐明,可为PHC的靶向治疗提供理论依据。Primary liver cancer(PHC) is a common malignant tumor.Its pathogenesis is not clear,and the treatment specificity is poor,so the therapeutic effect is not ideal.MicroRNA(miRNA/miR)-122 which is specifically highly expressed in liver is closely related to the occurrence of PHC.The low expression of miR-122 plays an important role in the onset,development,prognosis and liver cells differentiation of PHC.miR-122 participates in multiple biological processes of liver cancer cells by binding with its target genes or acting on relevant signaling pathways,thus playing a cancer inhibitive role.The Wnt/β-catenin signaling pathway and tumor-related genes such as cyclin G1,adisintegrin and metalloproteinase-10(ADAM10),insulin like growth factor-1 receptor and FOX family gene are important targets of miR-122.Further elucidation on the pathogenesis of PHC from the perspective of molecular biology can provide theoretical basis for the targeted therapy of PHC.

关 键 词：肝癌 微RNA 细胞周期蛋白G1 解整合素-金属蛋白酶 Wnt/β联蛋白信号通路 肿瘤相关基因 

分 类 号：R735.7[医药卫生—肿瘤]